Compare Novo Nordisk A/S (NVO) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Victoria's Secret & Co — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Victoria's Secret & Co trades at $82.87 (market cap $6.91B). The key difference: Novo Nordisk A/S is far larger — about 23.9× Victoria's Secret & Co's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Victoria's Secret & Co for 34 Days on average.
| NVO | VSXY | |
|---|---|---|
Market Cap | $165.31B | $6.91B |
Volume | 11,432,838 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $99.97 |
52-Week Low | $35.29 | $28.25 |
Typical Hold Time | 116 Days | 34 Days |
Enterprise Value | $179.56B | $9.29B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Victoria's Secret (VSXY) trades at $86.61, up 0.96% with strong technical momentum and bullish moving average signals. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and a projected 2026 net income rebound to $378M. Recent news highlights brand momentum through fashion show expansion and omnichannel growth, though valuation remains elevated at P/E 19.33.
The outlook appears positive with 60% analyst buy ratings and $86.80 consensus target, but risks include rich valuation, rising costs, and competitive pressures. Earnings growth acceleration and international expansion provide catalysts, while margin sustainability and consumer demand volatility present challenges for sustained shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
